Kala Pharmaceuticals (KALA) Financials

$0.51

$-0.05 (-9.57%)

As on 04-Sep-2026 19:31EDT

Market cap

$10 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	3.89	11.24
Cost of Revenue	0.18	0.32	0.26	0.30	2.56	4.10
Gross Profit	-0.18	-0.32	-0.26	-0.30	1.33	7.14
Operating Expenses	20.99	39.16	40.18	38.85	82.69	116.58
Operating Profit (EBIT)	-20.99	-39.16	-40.43	-39.15	-81.36	-109.43
Other Income	--	--	--	--	--	--
Profit before Tax	-10.08	-26.98	-38.51	-42.20	-44.82	-142.61
Provision for Tax	--	--	--	--	-44.60	9.69
Profit after Tax (Net Income)	-10.08	-26.98	-38.51	-42.20	-44.82	-142.61
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-44.82	-142.61

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	9.04	7.00	12.33	7.50	18.97	16.80
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	26.20	40.10	42.16	85.20
Current Liabilities	1.54	2.49	16.96	8.35	25.69	37.42
Total Liabilities	12.12	9.49	55.48	55.95	86.82	139.43

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	--	--	2.69	3.08	0.88	15.06
Current Assets	10.58	9.49	52.80	52.87	85.94	124.37
Total Assets	12.12	9.49	55.48	55.95	86.82	139.43
Total Debt*	--	--	32.25	36.32	42.95	80.19
Net Current Assets	9.04	7.00	35.84	44.52	60.26	86.94

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-31.99	-29.38	-27.93	-78.91	-108.24
Cash Flow from Investing Activities	--	-0.02	-0.21	-0.43	62.72	70.80
Cash from Financing Activities	--	-11.62	29.88	8.51	-7.94	42.55
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-80.62	-48.44	-8.20	-15.56	-27.82	-109.61
Cash EPS ($)	--	-47.87	-8.15	-15.44	-27.48	-108.86
Adjusted Book Value ($)	--	12.56	2.63	2.77	11.77	12.92
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-57.43	-6.26	-10.30	-48.97	-83.19
Free Cash Flow per Share ($)	--	-57.43	-6.30	-10.52	-49.16	-83.87

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-104.61	-87.12	-79.81	-56.41	-95.74
ROE (%)	-125.69	-279.18	-388.29	-318.75	-250.56	-244.19
ROA (%)	-31.41	-83.05	-69.12	-59.12	-39.62	-79.00
EBIT Margin (%)	--	--	--	--	-964.95	-1,194.17
Net Margin (%)	--	--	--	--	-1,151.64	-1,268.73
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	-1.00	-0.65	0.77
EBIT Growth (%)	82.06	27.57	10.05	3.12	72.02	-39.48
Net Profit Growth (%)	72.92	29.94	8.74	5.85	68.57	-36.69
EPS Growth (%)	49.54	-4.90	0.47	0.44	0.75	-0.20
Book Value Growth (%)	595.38	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.01	-0.85	-0.45	-1.37	-0.01
Price / Book Value	1.12	0.04	2.64	2.53	3.24	0.09
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.16	0.31	-0.42	-0.12	-0.92	0.08
Close Price ($)	1.73	27.80	347.00	350.00	1,907.50	1,514.00
High Price ($)	1,030.00	1,030.00	462.50	2,836.00	2,427.38	12,473.75
Low Price ($)	1.63	25.50	210.50	255.00	177.22	1,388.88
Market Cap ($ Cr)	9.81	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	2.62	4.84	2.26	4.77
Short term debt to equity ratio	--	--	0.87	0.04	0.26	0.04
Current Ratio	6.88	3.81	3.11	6.33	3.35	3.32
Quick Ratio	6.88	--	--	--	3.05	3.09
Interest Coverage	-7.10	-7.24	-5.66	-6.26	-5.17	-16.02

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	166.93	155.29
Asset Turnover	--	--	--	--	0.03	0.06
Receivable days	--	--	--	--	1,123.90	443.71
Inventory Days	--	--	--	9,248.18	1,163.59	618.17
Payable days	--	929.83	1,090.81	1,969.70	517.06	295.22
Cash Conversion Cycle	--	--	--	--	1,770.44	766.66

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.